Edwards Surgical Structural Heart Therapies

Review the #COMMENCEtrial 7-year bicuspid aortic valve sub-analysis that demonstrated encouraging results for patients ≤ 65 years old with #RESILIAtissue valves. >>>See the findings https://ow.ly/nOwe50TRP2z ? Important Safety Info: https://ow.ly/bg2050TRP2y

A lot goes into selecting a valve for #mitralvalvesurgery. How do your peers weigh the options??? ??Learn how the MITRIS RESILIA mitral valve meets these needs https://ow.ly/1x2c50TLVp2 ??Watch #cardiacsurgeons highlight important valve considerations ??Important safety info: https://ow.ly/ZI2250TLVp1

??Tune into this thought-provoking podcast: https://ow.ly/scEc50THXkY ??? Edwards Lifesciences GM and SVP, Wayne Markowitz, sat down with DeviceTalks to discuss the evolving landscape of the structural heart space, and Edwards’ commitment to innovation by partnering with cardiac surgeons to address unmet patient needs.

Designed with future considerations in mind, the #RESILIA tissue #surgical valve portfolio is helping patients rethink what’s possible. Learn how RESILIA tissue valves can help patients meet their future more confidently. https://ow.ly/N9Py50TvP1s

The #RESILIA tissue #surgical valve portfolio is the result of innovation built on a proven platform—the Carpentier-Edwards PERIMOUNT valve platform, to be exact. Backed by 30 years of durability data, we continue to push performance forward. Learn more https://ow.ly/WZ3750TvOYY

The #RESILIA tissue surgical valve portfolio is pushing performance forward. Learn about the strong, growing base of clinical evidence, including the latest results of the ongoing #COMMENCE trial. Learn more https://ow.ly/ZpT050TvORp

Developed in the late 1950s by engineer and inventor Miles "Lowell" Edwards and surgeon Dr. Albert Starr, the Starr-Edwards valve was successfully implanted by Dr. Starr for the first time 64 years ago today. The Starr-Edwards valve marked the beginning of the modern era of heart valve disease treatment, laying the groundwork for numerous advancements in both mechanical and tissue replacement heart valves. We’re proud to continue the patient-focused work that first began with these two trailblazing innovators more than half a century ago. #Innovation #MedTech #HeartValveDisease

The next Etiology of #Mitral Valve Disease course is coming up! Join Dr. Kevin Accola and Richard J. Moro for a 2-day course with didactic lectures, Q&A, and live OR case observations. Course application required 30 days in advance, please contact your local rep for more info.

Did you miss the last Etiology of #Mitral Valve Disease course? Don’t worry, another is on the way. Gain a solid foundation on the optimal management of mitral valve disease in a live case observation. Contact your local rep for more information.

If you’re on TikTok, you may have seen JT’s uplifting and positive content encouraging people to take care of their heart health. He also uses his platform to spread #HeartHealth awareness after his experiences with several heart conditions. JT was born with a heart defect called #SubaorticStenosis, undergoing his first open heart surgery at age three. Just as the COVID-19 pandemic was beginning, he found out he needed surgery to repair a leaky mitral valve and replace his aortic valve and a portion of his ascending aorta. His doctor recommended an Edwards valve for JT’s aortic valve replacement. JT’s treatment was successful, and he has since helped to raise more than $1 million for the American Heart Association. ?? We’re thankful to JT for his efforts to spread awareness about #HeartDisease and for sharing his story with us at the #PatientExperience. Stories like his are a powerful reminder of the importance of our work and how we can create positive change. #WhatMakesOurHeartsBeat #HeartOfInnovation #PatientStories